文献速递头颈外科

口咽癌经口机器人手术后长期功能与生活质量结局

Long-term Functional and Quality-of-Life Outcomes After Transoral Robotic Surgery in Patients With Oropharyngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2018-01-01

这项前瞻性纵向队列研究纳入74例接受经口机器人手术(TORS)治疗的口咽鳞状细胞癌(OPSCC)患者,比较单纯TORS与TORS联合放疗(TORS+RT)或放化疗(TORS+CRT)的长期功能与生活质量结局。结果显示三组术后疼痛和吞咽相关指标均显著恶化后随时间改善,但TORS+CRT组长期吞咽困难持续超过1年,单纯TORS组体重下降及进食相关评分优于联合辅助治疗组,支持探索辅助治疗降阶梯策略。

要点

  • TORS+CRT组术后1年以上仍存在持续吞咽困难,长期结局较差。
  • 单纯TORS组术后吞咽困难改善更快,长期体重下降及进食相关评分优于联合辅助治疗组。
  • 三组术后疼痛和吞咽相关指标均显著恶化,随后随时间改善但轨迹不同。

核心结论

  • 接受TORS+CRT的患者长期结局较差,术后1年以上仍存在持续吞咽困难,支持研究辅助治疗降阶梯策略以减少长期不良反应。

主要发现

  • 三组术后疼痛和所有吞咽相关指标均显著恶化,随后随时间改善但轨迹不同。
  • 单纯TORS组术后吞咽困难改善显著更快。
  • 长期随访时,单纯TORS组与TORS+RT组体重下降差异有临床意义(均数差-16.1;97.5%CI -29.8至-2.4)。
  • 长期随访时,单纯TORS组与TORS+CRT组体重下降差异有临床意义(均数差-14.6;97.5%CI -29.2至0)。
  • 单纯TORS组在Performance Status Scale-Eating in Public量表(均数差21.8;97.5%CI 4.3-39.2)和Head and Neck Quality of Life-Eating量表(均数差21.2;97.5%CI 4.0-38.3)评分显著优于TORS+CRT组。

临床怎么用

  • 对于接受TORS的OPSCC患者,应关注联合辅助放化疗者长期吞咽功能和生活质量,考虑辅助治疗降阶梯以减轻长期不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In recent years, transoral robotic surgery (TORS) has emerged as a useful treatment for oropharyngeal squamous cell carcinoma (OPSCC). In appropriately selected patients, the use of TORS may allow avoidance of adjuvant chemotherapy and/or radiotherapy, thereby avoiding the long-term adverse effects of these therapies. OBJECTIVE: To compare functional speech, swallowing, and quality-of-life outcomes longitudinally between those undergoing TORS only and those undergoing TORS and adjuvant radiotherapy (TORS+RT) or TORS and chemoradiotherapy (TORS+CRT). DESIGN, SETTING, AND PARTICIPANTS: This prospective, longitudinal cohort study performed from June 1, 2013, through November 31, 2015, included 74 patients undergoing TORS for initial treatment of OPSCC at a single tertiary academic hospital. MAIN OUTCOMES AND MEASURES: Data were collected at baseline, postoperatively (7-21 days), at short-term follow-up (6-12 months), and at long-term follow-up (>12 months). The quality-of-life metrics included the 10-item Eating Assessment Tool and the University of Michigan Head and Neck Quality of Life instrument. Data were also collected on tumor staging, surgical and adjuvant therapy details, patient comorbidities, tracheostomy and feeding tube use, and functional speech and swallowing status using the Performance Status Scale for Head and Neck Cancer Patients. RESULTS: Seventy-four patients were enrolled in the study (mean [SD] age, 61.39 [7.99] years; 68 [92%] male). Median long-term follow-up was 21 months (range, 12-36 months). The response rates were 86% (n = 64) postoperatively, 88% (n = 65) at short-term follow-up, and 86% (n = 64) at long-term follow-up. In all 3 groups, there was a significant worsening in pain and all swallowing-related measures postoperatively. There was subsequent improvement over time, with different trajectories observed across the 3 intervention groups. Postoperative dysphagia improved significantly more quickly in the TORS-only group. At long-term follow-up, weight loss differed between the TORS-only and TORS+RT groups (mean difference, -16.1; 97.5% CI, -29.8 to -2.4) and the TORS-only and TORS+CRT groups (mean difference, -14.6; 97.5% CI, -29.2 to 0) in a clinically meaningful way. In addition, the TORS-only group had significantly better scores than the TORS+CRT group on the Performance Status Scale-Eating in Public scale (mean difference, 21.8; 97.5% CI, 4.3-39.2) and Head and Neck Quality of Life-Eating scale (mean difference, 21.2; 97.5% CI, 4.0-38.3). CONCLUSIONS AND RELEVANCE: Patients who underwent TORS+CRT demonstrated poorer long-term outcomes, with continued dysphagia more than 1 year after surgery. These findings support the investigation of adjuvant de-escalation therapies to reduce the long-term adverse effects of treatment.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Achim V, Bolognone RK, Palmer AD, et al. Long-term Functional and Quality-of-Life Outcomes After Transoral Robotic Surgery in Patients With Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 29075740. doi:10.1001/jamaoto.2017.1790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。